These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31985084)

  • 1. Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?
    Pistone G; Tilotta G; Gurreri R; Castelli E; Curiale S; Bongiorno MR
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):e255-e256. PubMed ID: 31985084
    [No Abstract]   [Full Text] [Related]  

  • 2. Polyenthesitis during treatment with dupilumab for atopic dermatitis.
    Ishibashi M; Honda T; Tabuchi Y; Kabashima K
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e319-e321. PubMed ID: 31991016
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.
    Napolitano M; Caiazzo G; Fabbrocini G; Balato A; Di Caprio R; Scala E; Scalvenzi M; Patruno C
    Br J Dermatol; 2021 Feb; 184(2):341-343. PubMed ID: 33533476
    [No Abstract]   [Full Text] [Related]  

  • 4. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular surface disease associated with dupilumab treatment for atopic diseases.
    Utine CA; Li G; Asbell P; Pflugfelder S; Akpek E
    Ocul Surf; 2021 Jan; 19():151-156. PubMed ID: 32439390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.
    Waldman RA; DeWane ME; Sloan SB; King B; Grant-Kels JM
    J Am Acad Dermatol; 2021 Sep; 85(3):735-736. PubMed ID: 31325553
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
    Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
    Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angioedema: A potential complication of dupilumab in atopic dermatitis.
    Fritz AL; Lacy FA; Morrell DS
    Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
    Bortoluzzi P; Ferrucci S; Galimberti D; Garavelli F; Pozzo Giuffrida F; Pizzati A; Marzano AV; Mapelli C
    Br J Dermatol; 2022 Jan; 186(1):186-187. PubMed ID: 34431510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients.
    Wang Y; Jorizzo J
    Int J Dermatol; 2021 Sep; 60(9):e382. PubMed ID: 33715168
    [No Abstract]   [Full Text] [Related]  

  • 13. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
    Hendricks AJ; Yosipovitch G; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab-induced ocular surface disease: a primer.
    Reji MA; Haque A; Goyal S; Krishnaswamy G
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35414583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on "Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry".
    Seo HM; Oh SU; Park SK; Kim JS
    J Am Acad Dermatol; 2021 Sep; 85(3):e171. PubMed ID: 33667539
    [No Abstract]   [Full Text] [Related]  

  • 17. Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.
    Takeuchi S; Inoue K; Kuretake K; Kiyomatsu-Oda M; Furue M
    J Dermatol; 2021 May; 48(5):638-644. PubMed ID: 33742710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis.
    Rohner MH; Thormann K; Cazzaniga S; Yousefi S; Simon HU; Schlapbach C; Simon D
    Allergy; 2021 Apr; 76(4):1268-1270. PubMed ID: 33210741
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to: "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'".
    Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
    J Am Acad Dermatol; 2021 Sep; 85(3):e173-e174. PubMed ID: 33675862
    [No Abstract]   [Full Text] [Related]  

  • 20. Dupilumab improved atypical fibrotic skin plaques in atopic dermatitis.
    Nakashima C; Ishida Y; Kaku Y; Epstein EH; Otsuka A; Kabashima K
    Br J Dermatol; 2020 Feb; 182(2):487-488. PubMed ID: 31325158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.